Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spleen aminopeptide oral lyophilized powder plus platinum chemotherapy in advanced non-small cell lung cancer
ChiCTR-IPR-17013732Phase 4Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Dec 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of spleen polypeptide in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Quality of life improvement on Day 42. Started Dec 2017; status: recruiting.
02
Drugs
spleen polypeptide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IPR-17013732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013732.